Category: The Pharma Industry Personalized Medicine New Drug Pipeline and R&D Information Technology and Software Pharmaceutical Patents and Intellectual Property Pharmaceutical Industry CEOs Pharmaceutical Industry Goodwill and Philanthropy Environmental issues and green pharma Supply Chain Management management Drug pricing drug development DIA IBM Life Sciences patient-centered healthcare pandemic monitoring and surveillance Mike Svinte
Submitted by pharmamanufacturing on Wed, 06/25/2008 - 11:11
At a meeting at DIA in Boston yesterday, Mike Svinte, President of Global Life Sciences at IBM provided a sneak peek and insights into a new report probing CEO challenges and concerns and their implications. The report, which is due to be released next month, will distill interviews with more...
Category: Miscellany Genzyme Pharmaceutical Industry Goodwill and Philanthropy Drug pricing BIO 2008 San Diego drug development Gates Foundation orphan drugs Avant Immunotherapeutics Ltd. Commons Capital
Submitted by pharmamanufacturing on Fri, 06/20/2008 - 10:49
On Tuesday afternoon, a panel discussed ways in which corporations might be able to stimulate the development of more therapies for serious diseases----the world’s top killers such as malaria. The topic is one that I’m very interested, but, unfortunately, I arrived late and missed much of the discussion.
Category: Lean Six Sigma and Quality Improvement Drug Safety The Pharma Industry Pfizer New Drug Pipeline and R&D Drug Marketing and Sales Pharma Workforce and Staffing Eli Lilly management Drug pricing medical research Schering-Plough Nektar
Submitted by pharmamanufacturing on Wed, 04/09/2008 - 10:35
Clinical trials may have uncovered a possible link between inhaled insulin and lung cancer. In testing its blockbuster manque Exubera, Pfizer said six of the 4,740 Exubera-treated patients versus one of the 4,292 patients not treated with Exubera developed lung cancer.
Category: Lean Six Sigma and Quality Improvement The Pharma Industry New Drug Pipeline and R&D Drug Marketing and Sales Whistleblowers Merck management Drug pricing
Submitted by pharmamanufacturing on Thu, 02/07/2008 - 14:20
Unfortunately, there is a "Jekyll and Hyde" aspect to many pharma companies today as they struggle with the dictates of shareholders and the whole blockbuster model. Nowhere was that more evident today than in two articles received within hours of each other.
Category: The Pharma Industry Vaccines Wyeth Pharmaceutical Industry Goodwill and Philanthropy management Drug pricing
Submitted by pharmamanufacturing on Wed, 11/28/2007 - 21:59
Oxfam just released a report on the development of drugs to treat the most prevalent diseases in developing nations. For a summary and to download the report, click here. It cites an unnamed consulting group that has put a price tag on the neglect.
Submitted by pharmamanufacturing on Thu, 11/01/2007 - 16:03
Pharmaceutical companies are constantly being berated/fined for overzealous salespeople selling drugs off label to doctors/pharmacies. In the recent case of Genentech's Avastin, the shoe appears to be on the proverbial other foot. Earlier this month, Genentech made the decision to restrict the availability of Avastin to compounding pharmacies.
Submitted by pharmamanufacturing on Mon, 07/09/2007 - 16:59
The Academy of Managed Care Pharmacy has developed and placed on its website a searchable interactive database of articles and documents that examine drug product payment systems in use in the United States today, such as average wholesale price (AWP), average manufacturer's price (AMP) and wholesale average cost (WAC).